1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22468, 2009-012072-28, NCT01056510
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25136, NCT01271010
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25137, NCT01283386
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: RJ-2010-56, NCT01358253
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO25455, 2010-023407-95, NCT01461928
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NHL 7-2008, NCT00877214
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
|
|
13.
|
Phase: Phase III, Phase II
Type: Natural history/Epidemiology, Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 201010HBV, NCT01210287
|
|
14.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172
|
|
15.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI
Protocol IDs: COG-ANHL1131, ANHL1131, NCT01595048
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: NCI
Protocol IDs: SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2000-06, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCBX001-049, NCT00078598
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRUK-2004-001621-16, EU-20509, ROCHE-CRUK-001621-16, NCT00112931
|
|
20.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TROG 99.03, ALLG NHLLOW5, NCT00115700
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LMBA02, NCT00180882
|
Mobile | Español
